|
July 7, 2022
|
Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform
|
|
June 22, 2022
|
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
|
|
May 31, 2022
|
Biora Therapeutics Shares Presentation of Patient Data Establishing Correlation Between Drug Levels in Colon and Patient Outcomes in Ulcerative Colitis
|
|
May 25, 2022
|
Biora Therapeutics Shares Data Presented at Digestive Disease Week 2022
|
|
May 19, 2022
|
Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform
|
|
May 16, 2022
|
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Global Investment Conference
|
|
May 10, 2022
|
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
|
|
May 5, 2022
|
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
|
|
May 3, 2022
|
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
|
|
April 25, 2022
|
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
|